Why the study?
Does recipient/donor CMV seropositivity status affect the intensity of CMV infection and frequency of acute heart allograft rejection in heart transplant recipients?
Does recipient/donor CMV seropositivity status affect the intensity of CMV infection and frequency of acute heart allograft rejection in heart transplant recipients?
In heart transplant recipients, donor CMV seropositivity increases the severity of CMV infection in seronegative recipients, but CMV infection does not appear to correlate with acute biopsy-proven rejection.
Recipient CMV seropositivity may lessen post-transplant infection severity; leaves open any causal CMV-rejection link in heart allografts.
A scoring table to quantify the intensity (average clinical score) of CMV infection in 54 heart allograft recipients was created. Scores were assigned on the basis of presence and severity of each particular clinical CMV‐related symptom or sign. In total, 35 CMV infections occurred in 54 patients (65%). Symptomatic CMV infection developed in 19 patients (35%) of which 7 were primary infections and 11 reactivations/reinfections. It was noticed that the seropositive donor had a significant influence on the outcome of the seronegative recipient: all 7 symptomatic primary infections occurred in recipients with seropositive allografts (p<0.05). The severity of infection in preoperalively seropositive recipients was significantly milder than that in seronegalivce recipients with seropositive donors (clinical score 2.25 vs. 5.43, respectively; p<0.05). In our study no correlation between CMV infection and acute biopsy proven rejection could be found.
No takes yet. Share an insight, caveat, or question.
Lemström et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: